<\/b><\/p>\n
<\/b><\/p>\n
WEDNESDAY, May 20, 2020 (HealthDay News) — For patients with diabetes and COVID-19, risk factors for mortality include older age and elevated C-reactive protein, and insulin usage is associated with poor prognosis, according to a study published online May 14 in Diabetes Care<\/i>.<\/p>\n
Yuchen Chen, from the Huazhong University of Science and Technology in Wuhan, China, and colleagues conducted a retrospective study involving 904 patients with COVID-19 (136 with diabetes) to compare clinical and laboratory characteristics between the groups with and without diabetes. The authors examined risk factors associated with mortality or poor prognosis.<\/p>\n
The researchers found that between cases of confirmed and clinically diagnosed COVID-19, the proportion of comorbid diabetes was similar. For patients with diabetes and COVID-19, risk factors for higher mortality included older age (adjusted odds ratio, 1.09 [95 percent confidence interval, 1.04 to 1.15] per year increase; P = 0.001) and elevated C-reactive protein (adjusted odds ratio, 1.12; 95 percent confidence interval, 1.00 to 1.24; P = 0.043). There was an association for insulin usage with poor prognosis (adjusted odds ratio, 3.58; 95 percent confidence interval, CI 1.37 to 9.35; P = 0.009). For patients with diabetes and hypertension who had COVID-19, clinical outcomes were comparable for those using an angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II type-1 receptor blocker (ARB) and those who did not use ACEIs\/ARBs.<\/p>\n
“Insulin usage was associated with poor prognosis, suggesting that more attention is needed regarding patients with COVID-19 who have diabetes and use insulin,” the authors write. “Neither comorbid hypertension nor ACEI\/ARB medication use had a significant impact on clinical outcomes of patients with diabetes and COVID-19.”<\/p>\n
Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n